Key result
Epicardial radiofrequency ablation cuts ventricular arrhythmia recurrence ~83% and ICD shocks in Brugada syndrome.
Why the study?
This study evaluated the long-term efficacy of epicardial radiofrequency ablation in preventing ventricular arrhythmia recurrence in patients with Brugada syndrome.
Does radiofrequency ablation reduce ventricular arrhythmia recurrence and all-cause mortality in patients with Brugada syndrome?
Meta-Analysis
Does radiofrequency ablation reduce ventricular arrhythmia recurrence and all-cause mortality in patients with Brugada syndrome?
Epicardial radiofrequency ablation significantly reduces recurrent ventricular arrhythmias and ICD shocks in patients with Brugada syndrome, with a favorable long-term safety profile.
Answers are grounded in this paper and cite their sources.
May support epicardial ablation to curb VA recurrence and ICD shocks in Brugada syndrome; extends pooled evidence but awaits RCT confirmation.
Background Brugada syndrome ( BrS ) is a rare cardiac channelopathy linked to an increased risk of ventricular arrhythmias ( VA ) and sudden cardiac death. Radiofrequency ablation ( RFA ), particularly epicardial ablation, is recommended for BrS patients with recurrent VA unresponsive to conventional treatments like implantable cardioverter‐defibrillators ( ICD ) and quinidine. This study aims to evaluate the long‐term efficacy of epicardial RFA in preventing VA recurrence in BrS . Methods A systematic search of PubMed , ScienceDirect , Cochrane Library, and ProQuest databases was conducted following PRISMA 2020 guidelines. Studies on RFA for VA in BrS were included. Primary outcomes were VA recurrence and all‐cause mortality. Statistical analysis was performed using Review Manager 5.4. Results Epicardial, endocardial, and combined ablation strategies effectively reduced VA recurrence, decreased ICD shocks, and improved clinical outcomes in BrS . Epicardial ablation RFA near coronary arteries showed a notable reduction in VA recurrence, while endocardial ablation remained a viable alternative. Meta‐analysis revealed a significant reduction in VA recurrence ( RR 0.17; 95% CI 0.07–0.43; p < .0001) and ICD shocks ( RR 0.13; 95% CI 0.04–0.44; p = .001). Subgroup analysis suggested greater VA reduction with epicardial ablation, though without statistical significance. Conclusion Epicardial RFA is associated with a significant reduction in recurrent VAs (83%) and ICD shock rates (87%) in patients with BrS . The procedure demonstrates a favorable long‐term safety profile, with no mortality reported in the included studies.
No takes yet. Share an insight, caveat, or question.
Adji et al. (2025) conducted a meta-analysis in Brugada syndrome (BrS). Epicardial radiofrequency ablation was evaluated on Ventricular arrhythmia recurrence (RR 0.17, 95% CI 0.07-0.43, p=<.0001). Epicardial radiofrequency ablation reduced ventricular arrhythmia recurrence and ICD shocks in patients with Brugada syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: